e20074 Background: This study aimed to evaluate the safety and efficacy of neoadjuvant
camrelizumab combined with chemotherapy in patients with resectable non-small cell lung …

Importance The benefit of neoadjuvant camrelizumab plus chemotherapy for resectable
stage IIIA or IIIB non–small cell lung cancer (NSCLC) remains unknown. Objective To …

Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally
advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and …

This multicentre, two-arm, phase 2 study aimed to explore the efficacy and safety of
neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially …

Background Our phase 2 trial was the first to report the efficacy and safety of neoadjuvant
chemo-free regimen with camrelizumab and apatinib in patients with resectable non-small …

Background Resectable NSCLC with neoadjuvant chemotherapy (CT) has favourable
outcomes. However, with few neoadjuvant immunotherapy trials, detailed information on …

Background Camrelizumab has shown encouraging efficacy in advanced non-small cell
lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However …

Camrelizumab is a novel programmed cell death protein 1 (PD‑1) inhibitor developed in
China that exhibits good efficacy in several advanced cancer types, including non‑small cell …

Background Pembrolizumab has been shown to be effective and safe in improving the
survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the …

Background Camrelizumab (anti-PD-1 antibody) monotherapy or combined with
chemotherapy showed efficacy for advanced NSCLC in trials. However, the real-world data …